BioSphere Pitches Uterine Fibroid Embolization Alternative To Hysterectomy
This article was originally published in The Gray Sheet
Executive Summary
BioSphere Medical maintains that 180,000 additional women per year who would normally receive hysterectomies will be candidates for its Embosphere Microspheres uterine fibroid embolization now that the procedure has received FDA go-ahead
You may also be interested in...
UAE FIBROID Registry Unlikely To Deliver Conclusive Post-Op Fertility Data
Insufficient data from the uterine artery embolization FIBROID registry will necessitate further investigation to assess the impact of the procedure on fertility and future pregnancies, according to James Spies, MD, Georgetown University Medical Center
UAE FIBROID Registry Unlikely To Deliver Conclusive Post-Op Fertility Data
Insufficient data from the uterine artery embolization FIBROID registry will necessitate further investigation to assess the impact of the procedure on fertility and future pregnancies, according to James Spies, MD, Georgetown University Medical Center
Biocompatibles’ Drug-Eluting UFE Treatment Would Be Marketed By Terumo
Biocompatibles International may await development of a drug-eluting version of its Bead Block microspheres therapy before seeking FDA clearance for uterine fibroid embolization (UFE)